



PHARMACY FACTS

*Current information for pharmacists about
the MassHealth Pharmacy Program*

www.mass.gov/lists/masshealth-pharmacy-facts-2016-current

Editor: Ryan Bettencourt

Contributors: Eliza Anderson, Sarah Dube, Aimee Evers, Breeyn Green, Neha Kashalikar,
Kim Lenz, Mckenzie McVeigh, Katelyn Meyer, Kyle Semmel

Upcoming Changes to Health Safety Net (HSN) Reimbursement of Medications to Prevent Human Immunodeficiency Virus (HIV)

The HSN changed the management of the HSN formulary on January 12, 2026. More information is on the MassHealth Drug List HSN Formulary page. Please see Pharmacy Facts 258, 265, 267, 270, and 283 for more information on HSN formulary changes.

Effective October 1, 2026, HSN Is Changing the Management of Medications used for Pre-exposure Prophylaxis (PrEP) and Post-exposure Prophylaxis (PEP)

Effective October 1, 2026, HSN will require prior authorization (PA) for reimbursement of most brand medications used for PrEP and PEP. Injectable medications used for PrEP will still be reimbursable without PA when billed through the medical setting. Patients should be switched to a reimbursable alternative or have a PA submitted documenting medical necessity for use over reimbursable alternatives. More information on upcoming changes in HSN management of PrEP and PEP is described in the following table.

Reimbursable PrEP and PEP Medications Effective October 1, 2026

Health Safety Net Pharmacy Changes to Management of PrEP and PEP		
Indication	Reimbursable without PA	Reimbursable with PA*
PrEP	tenofovir disoproxil fumarate /emtricitabine	Apretude (cabotegravir) [†] Descovy (tenofovir alafenamide /emtricitabine) Yeztugo (lenacapravir) [†]
PEP	Isentress (raltegravir), ≤28 day supply every 90 days tenofovir disoproxil fumarate /emtricitabine Tivicay (dolutegravir), ≤28 day supply every 90 days	Biktarvy (bictegravir/emtricitabine /tenofovir alafenamide) Descovy (tenofovir alafenamide /emtricitabine)

*PA criteria require appropriate diagnosis, trial(s) of all clinically appropriate alternatives reimbursable without PA, or medical necessity for use instead of alternatives reimbursable without PA.

[†]The HSN formulary is not changing for drugs billed through the medical setting. Patients may continue to access injectable PrEP agents billed through the medical setting. PA is required for injectable therapies billed through the pharmacy setting.

Billing of HIV Treatment Medications

HSN patients and providers impacted by these changes are also getting notified of these requirements. Emergency supplies are available and clinical judgement should be considered when determining days' supply.